During 12-week hydrochlorothiazide treatment 16 men suffering from uncomplicated essential hypertension were examined. Hemodynamic parameters were controlled by means of echocardiography. The volume of the circulating plasma was determined by the dye dilution method. There was noted a significant decrease of systolic, diastolic, and the mean BP. During the first days of treatment there was observed a significant reduction of left ventricular end-diastolic and stroke volumes (EDV and SV) as well as minute volume (MV). Heart rate and indices of myocardial pump function did not change. On the 12th week of treatment there was noted a significant increase of EDV, SV, and MV, and total peripheral vascular resistance decreased as compared with the initial level. In 9 (56%) out of 16 patients 15.6 g decrease was observed in left ventricular myocardial mass (LVMM) on the average for the group during the 12th week of treatment. The decrease in LVMM was preceded by the decrease in the maximum intracardiac tension on the 3rd week of treatment which, probably, may serve a prognostic criterion of changes in LVMM in the prolonged treatment with diuretics.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Testing a Web-Based Interactive Comic Tool to Decrease Obesity Risk Among Racial and Ethnic Minority Preadolescents: Randomized Controlled Trial.
JMIR Form Res
January 2025
Graduate School of Public Health Policy, City University of New York, New York, NY, United States.
Background: Childhood obesity prevalence remains high, especially in racial and ethnic minority populations with low incomes. This epidemic is attributed to various dietary behaviors, including increased consumption of energy-dense foods and sugary beverages and decreased intake of fruits and vegetables. Interactive, technology-based approaches are emerging as promising tools to support health behavior changes.
View Article and Find Full Text PDFSuccessful Achievement of Demanding Outcomes in Upadacitinib-Treated Atopic Dermatitis Patients: A Real-World, 96-Week Single-Centre Study.
Dermatol Ther (Heidelb)
January 2025
1st Department of Dermatology and Venereology, Medical School of Athens, Andreas Sygros Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Introduction: Results from randomized controlled trials of upadacitinib, a Janus kinase (JAK) inhibitor, have led to its approval for the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged ≥ 12 years. The aim of this study was to report the effectiveness and safety of upadacitinib in real-world settings over a period of 96 weeks.
Methods: This retrospective study included all patients treated with upadacitinib at our centre between April 2022 and September 2024.
Benefits of a 12-week psychotherapy course for people with Parkinson's disease: a service improvement project.
J Neurol
January 2025
Imperial College London, Hammersmith Hospital, Hammersmith Campus, ICTEM Building, Ground Floor, Du Cane Road, London, W12 0NN, UK.
The psychological symptoms of Parkinson's disease (PD) worsen the quality of life of patients and their partners. However, these non-motor symptoms (mainly anxiety and depression) remain undiagnosed and undertreated in PD. Here, we report the benefits of a 12-week intervention using talking therapy (psychotherapy and counselling).
View Article and Find Full Text PDFOcrelizumab dose selection for treatment of pediatric relapsing-remitting multiple sclerosis: results of the OPERETTA I study.
J Neurol
January 2025
Division of Child Neurology, Children's Hospital of Philadelphia, Departments of Neurology and Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Background: The presented study identified the appropriate ocrelizumab dosing regimen for patients with pediatric-onset multiple sclerosis (POMS).
Methods: Patients with POMS aged 10-17 years were enrolled into cohort 1 (body weight [BW] < 40 kg, ocrelizumab 300 mg) and cohort 2 (BW ≥ 40 kg, ocrelizumab 600 mg) during a 24-week dose-exploration period (DEP), followed by an optional ocrelizumab (given every 24 weeks) extension period.
Primary Endpoints: pharmacokinetics, pharmacodynamics (CD19 B-cell count); secondary endpoint: safety; exploratory endpoints: MRI activity, protocol-defined relapses, Expanded Disability Status Scale (EDSS) score change.
Clinical consequence of the 4-week X-ray control after ESIN osteosynthesis of forearm fractures in children.
Eur J Trauma Emerg Surg
January 2025
Department of Orthopaedics and Traumatology, University Medical Center of the Johannes Gutenberg University, 55131, Mainz, Germany.
Purpose: The absence of evidence based general guidelines for radiographic follow-ups of pediatric diaphyseal forearm fractures treated with ESIN results in an arbitrary array of X-ray examinations. In most pediatric traumatology departments, an X-ray check is carried out 4 weeks after ESIN osteosynthesis of forearm shaft fractures to detect incipient consolidation of the fracture. However, the elevated sensitivity to ionizing radiation requires special precautions in the pediatric populations.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!